JP Morgan has recently reduced Novavax Inc (NVAX) stock to Underweight rating, as announced on July 30, 2024, according to Finviz. Earlier, on May 10, 2024, JP Morgan had raised the stock from a ...

Shortly after President-elect Donald J. Trump nominated Robert F. Kennedy Jr. to lead the Department of Health and Human ...

Novavax Inc. had an impressive 2024, with its stock gaining nearly 68%. The momentum has continued into 2025, with shares up ...

JP Morgan has recently reduced Novavax Inc (NVAX) stock to Underweight rating, as announced on July 30, 2024, according to Finviz. Earlier, on May 10, 2024, JP Morgan had raised the stock from a ...

Shares of Novavax Inc. NVAX shed 3.02% to $9.32 Friday, on what proved to be an all-around rough trading session for the ...

Novavax shares are trading higher by 12.4% during Tuesday's session. A recent CDC report highlights a sharp increase in ...

NOVAVAX INC (NVAX) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 41% based on the firm’s underlying fundamentals and the stock’s valuation.

Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the ...

Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store. Things were looking up for Novavax stock after the FDA ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.